/ANRO
ANRO Stock - Alto Neuroscience, Inc.
Healthcare|BiotechnologyNYSE
$19.98+2.72%
+$0.53 (+2.72%) • Dec 19
39
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).10
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-19.9%upside
Target: $16.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ANRO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$19.78 – $20.18
TARGET (TP)$16.00
STOP LOSS$18.38
RISK/REWARD1:-2.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.02
52W High$20.91
52W Low$1.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $210,000 |
| Gross Profit | $-502,000 | N/A | $-342,000 | $65,000 |
| Gross Margin | N/A | N/A | N/A | 31.0% |
| Operating Income | $-68,610,000 | $-37,809,000 | $-29,192,000 | $-12,056,000 |
| Net Income | $-61,431,000 | $-36,305,000 | $-27,710,000 | $-9,187,000 |
| Net Margin | N/A | N/A | N/A | -4374.8% |
| EPS | $-2.50 | $-1.35 | $-1.08 | $-0.36 |
Company Overview
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
80%
Hold / Neutral
2
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish2 Neutral/Bearish
Price Targets
$24
Average Target
↑ 21.0% Upside
Now
$4
Low
$24
Average
$33
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 17th 2025 | BTIG Research | Initiation | Buy | - |
| September 29th 2025 | Chardan Capital Markets | Initiation | Buy | $15 |
| October 23rd 2024 | Wedbush | Downgrade | Neutral | $4← $29 |
| October 23rd 2024 | Rodman & Renshaw | Downgrade | Neutral | - |
| September 3rd 2024 | Wedbush | Initiation | Outperform | $29 |
| February 27th 2024 | William Blair | Initiation | Outperform | - |
| February 27th 2024 | TD Cowen | Initiation | Outperform | - |
| February 27th 2024 | Robert W. Baird | Initiation | Outperform | $32 |
| February 27th 2024 | Jefferies | Initiation | Buy | $33 |
| February 27th 2024 | Stifel | Initiation | Buy | $32 |
Earnings History & Surprises
ANROBeat Rate
63%
Last 8 quarters
Avg Surprise
-47.0%
EPS vs Estimate
Beats / Misses
5/3
Last 12 quarters
Latest EPS
$-0.52
Q4 2025
EPS Surprise History
Q1 24
-365.3%
$-7.77vs$-1.67
Q2 24
-65.2%
$-0.76vs$-0.46
Q3 24
+15.5%
$-0.60vs$-0.71
Q4 24
+7.5%
$-0.62vs$-0.67
Q1 25
+13.8%
$-0.56vs$-0.65
Q2 25
+10.2%
$-0.53vs$-0.59
Q3 25
-14.0%
$-0.65vs$-0.57
Q4 25
+21.2%
$-0.52vs$-0.66
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 19, 2026 | $-0.56 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.66 | $-0.52 | +21.2% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.57 | $-0.65 | -14.0% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.59 | $-0.53 | +10.2% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.65 | $-0.56 | +13.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.67 | $-0.62 | +7.5% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.71 | $-0.60 | +15.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.46 | $-0.76 | -65.2% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-1.67 | $-7.77 | -365.3% | ✗ MISS |
Q1 2024 | Feb 5, 2024 | — | $-0.34 | — | — |
Q2 2023 | Jun 29, 2023 | — | $-0.32 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.27 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.30 | — | — |
Latest News
BTIG Initiates Coverage On Alto Neuroscience with Buy Rating, Announces Price Target of $27
📈 PositiveBenzinga•Nov 17, 2025, 10:49 AM
Baird Maintains Outperform on Alto Neuroscience, Raises Price Target to $22
📈 PositiveBenzinga•Nov 13, 2025, 12:35 PM
Jefferies Maintains Buy on Alto Neuroscience, Raises Price Target to $25
📈 PositiveBenzinga•Nov 12, 2025, 07:38 PM•Also:
Alto Neuroscience Q3 EPS $(0.52) Beats $(0.67) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:58 PM
HC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $50
📈 PositiveBenzinga•Oct 24, 2025, 10:26 AM•Also:
Baird Maintains Outperform on Alto Neuroscience, Raises Price Target to $16
📈 PositiveBenzinga•Oct 20, 2025, 05:55 PM
ANRO stock has given up its prior loss. Alto Neuroscience shares were trading lower after the company announced a $50 million private placement to accelerate the development of ALTO-207 in treatment resistant depression.
➖ NeutralBenzinga•Oct 20, 2025, 01:56 PM
Alto Neuroscience shares are trading lower after the company announced a $50 million private placement to accelerate the development of ALTO-207 in treatment resistant depression.
📉 NegativeBenzinga•Oct 20, 2025, 01:25 PM
Alto Neuroscience Expects To Initiate A Phase 3 Study Of ALTO-207 In TRD Patients By Early 2027
📈 PositiveBenzinga•Oct 20, 2025, 11:14 AM
Alto Neuroscience Announces $50M Private Placement To Accelerate Development Of ALTO-207 In Treatment Resistant Depression
📈 PositiveBenzinga•Oct 20, 2025, 11:12 AM
Alto Neuroscience Says FDA Grants Fast Track Designation To ALTO-101 For Treatment Of Cognitive Impairment Associated With Schizophrenia
📈 PositiveBenzinga•Oct 3, 2025, 11:35 AM
Chardan Capital Initiates Coverage On Alto Neuroscience with Buy Rating, Announces Price Target of $15
📈 PositiveBenzinga•Sep 29, 2025, 11:24 AM
Alto Neuroscience Reports Replication Study Results Validating EEG Biomarkers in Schizophrenia
📈 PositiveBenzinga•Sep 9, 2025, 11:16 AM
HC Wainwright & Co. Reiterates Buy on Alto Neuroscience, Maintains $10 Price Target
📈 PositiveBenzinga•Aug 18, 2025, 05:11 PM
Alto Neuroscience Posts Q2 Net Loss
📉 NegativeThe Motley Fool•Aug 13, 2025, 09:37 PM
Frequently Asked Questions about ANRO
What is ANRO's current stock price?
Alto Neuroscience, Inc. (ANRO) is currently trading at $19.98 per share. The stock has moved +2.72% today.
What is the analyst price target for ANRO?
The average analyst price target for ANRO is $16.00, based on 1 analyst.
What sector is Alto Neuroscience, Inc. in?
Alto Neuroscience, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is ANRO's market cap?
Alto Neuroscience, Inc. has a market capitalization of $0.62 billion, making it a small-cap company.
Does ANRO pay dividends?
No, Alto Neuroscience, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$11.74
Mkt Cap: $0.3B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
DRTS
Alpha Tau Medical Ltd.
$5.07
Mkt Cap: $0.4B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to ANRO for comparison